Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
74% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZY' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.91
ENZY's Equity to Asset is ranked higher than
85% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZY: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
ENZY' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.92 Max: 0.93
Current: 0.91
0.67
0.93
Interest Coverage 27.29
ENZY's Interest Coverage is ranked lower than
79% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: 27.29 )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 30.19 Max: 52.46
Current: 27.29
8.09
52.46
F-Score: 5
Z-Score: 7.55
M-Score: -2.76
WACC vs ROIC
9.27%
1.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.17
ENZY's Operating margin (%) is ranked higher than
74% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. ENZY: 4.17 )
Ranked among companies with meaningful Operating margin (%) only.
ENZY' s Operating margin (%) Range Over the Past 10 Years
Min: -1.51  Med: 14.04 Max: 18.1
Current: 4.17
-1.51
18.1
Net-margin (%) 4.82
ENZY's Net-margin (%) is ranked higher than
75% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. ENZY: 4.82 )
Ranked among companies with meaningful Net-margin (%) only.
ENZY' s Net-margin (%) Range Over the Past 10 Years
Min: -3.75  Med: 13.26 Max: 17.54
Current: 4.82
-3.75
17.54
ROE (%) 1.75
ENZY's ROE (%) is ranked higher than
76% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. ENZY: 1.75 )
Ranked among companies with meaningful ROE (%) only.
ENZY' s ROE (%) Range Over the Past 10 Years
Min: -3.14  Med: 5.04 Max: 6.52
Current: 1.75
-3.14
6.52
ROA (%) 1.61
ENZY's ROA (%) is ranked higher than
79% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. ENZY: 1.61 )
Ranked among companies with meaningful ROA (%) only.
ENZY' s ROA (%) Range Over the Past 10 Years
Min: -1.89  Med: 5.71 Max: 12.16
Current: 1.61
-1.89
12.16
ROC (Joel Greenblatt) (%) 4.65
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. ENZY: 4.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -0.51  Med: 13.81 Max: 28.12
Current: 4.65
-0.51
28.12
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ENZY Guru Trades in Q4 2015

Jim Simons 217,700 sh (+49.11%)
Julian Robertson 1,162,845 sh (+44.48%)
John Paulson 4,238,275 sh (unchged)
» More
Q1 2016

ENZY Guru Trades in Q1 2016

John Paulson 4,224,139 sh (-0.33%)
Julian Robertson 1,143,145 sh (-1.69%)
Jim Simons 181,000 sh (-16.86%)
» More
Q2 2016

ENZY Guru Trades in Q2 2016

Jim Simons 241,000 sh (+33.15%)
John Paulson 4,224,139 sh (unchged)
Julian Robertson 577,407 sh (-49.49%)
» More
Q3 2016

ENZY Guru Trades in Q3 2016

Julian Robertson 677,548 sh (+17.34%)
Jim Simons 258,300 sh (+7.18%)
John Paulson 4,205,980 sh (-0.43%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RGLS, NAS:AKAO, NAS:AXSM, NAS:ABUS, NAS:AVXL, NAS:CASC, NAS:XENE, NAS:VVUS, NAS:NYMX, NAS:RDHL, OTCPK:OGRMF, OTCPK:SPRWF, AMEX:NAVB, NAS:OVAS, NAS:GTXI, OTCPK:PAIOF, NAS:ATHX, NAS:GLYC, NAS:FBIO, NAS:CXRX » details
Traded in other countries:EZ4.Germany,
Enzymotec Ltd develops, manufactures, markets & sells innovative bio-functional lipid ingredients, and final products, based on sophisticated proprietary processes & technologies. The Company's segments include Nutrition Segment & VAYA Pharma Segment.

Top Ranked Articles about Enzymotec Ltd

Julian Robertson Sells Half of Stake in John Paulson-Backed Company Hedge fund pioneer was fourth largest shareholder of 'medical foods' company
Roughly a year after starting to invest in the company, Julian Robertson (Trades, Portfolio) has chopped half his stake in Enzymotec Ltd. (NASDAQ:ENZY), a maker of nutritional ingredients and medical foods. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 55.92
ENZY's P/E(ttm) is ranked lower than
73% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. ENZY: 55.92 )
Ranked among companies with meaningful P/E(ttm) only.
ENZY' s P/E(ttm) Range Over the Past 10 Years
Min: 14.53  Med: 32.07 Max: 66.64
Current: 55.92
14.53
66.64
PE(NRI) 55.92
ENZY's PE(NRI) is ranked lower than
73% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. ENZY: 55.92 )
Ranked among companies with meaningful PE(NRI) only.
ENZY' s PE(NRI) Range Over the Past 10 Years
Min: 14.53  Med: 32.07 Max: 66.64
Current: 55.92
14.53
66.64
P/B 1.02
ENZY's P/B is ranked higher than
90% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ENZY: 1.02 )
Ranked among companies with meaningful P/B only.
ENZY' s P/B Range Over the Past 10 Years
Min: 0.93  Med: 1.51 Max: 11.01
Current: 1.02
0.93
11.01
P/S 2.84
ENZY's P/S is ranked higher than
80% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ENZY: 2.84 )
Ranked among companies with meaningful P/S only.
ENZY' s P/S Range Over the Past 10 Years
Min: 1.26  Med: 3.51 Max: 5.88
Current: 2.84
1.26
5.88
PFCF 96.11
ENZY's PFCF is ranked lower than
85% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. ENZY: 96.11 )
Ranked among companies with meaningful PFCF only.
ENZY' s PFCF Range Over the Past 10 Years
Min: 21.46  Med: 41.56 Max: 451.3
Current: 96.11
21.46
451.3
POCF 39.43
ENZY's POCF is ranked lower than
72% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. ENZY: 39.43 )
Ranked among companies with meaningful POCF only.
ENZY' s POCF Range Over the Past 10 Years
Min: 10.93  Med: 23.21 Max: 686.67
Current: 39.43
10.93
686.67
EV-to-EBIT 33.70
ENZY's EV-to-EBIT is ranked lower than
70% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. ENZY: 33.70 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 24.6 Max: 51.4
Current: 33.7
7.2
51.4
EV-to-EBITDA 17.09
ENZY's EV-to-EBITDA is ranked lower than
53% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. ENZY: 17.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 18.4 Max: 34.9
Current: 17.09
6.3
34.9
Current Ratio 7.40
ENZY's Current Ratio is ranked higher than
68% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ENZY: 7.40 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.4 Max: 8.76
Current: 7.4
2.31
8.76
Quick Ratio 5.00
ENZY's Quick Ratio is ranked higher than
56% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ENZY: 5.00 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.5  Med: 5.4 Max: 7.31
Current: 5
1.5
7.31
Days Inventory 515.88
ENZY's Days Inventory is ranked lower than
95% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. ENZY: 515.88 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 169.63 Max: 515.88
Current: 515.88
121.07
515.88
Days Sales Outstanding 106.66
ENZY's Days Sales Outstanding is ranked lower than
74% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ENZY: 106.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 105.54  Med: 108.33 Max: 128.19
Current: 106.66
105.54
128.19
Days Payable 252.82
ENZY's Days Payable is ranked higher than
86% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ENZY: 252.82 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 72.95  Med: 107.56 Max: 252.82
Current: 252.82
72.95
252.82

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.63
ENZY's Price/Net Cash is ranked higher than
59% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. ENZY: 4.63 )
Ranked among companies with meaningful Price/Net Cash only.
ENZY' s Price/Net Cash Range Over the Past 10 Years
Min: 4.59  Med: 6.83 Max: 10.39
Current: 4.63
4.59
10.39
Price/Net Current Asset Value 1.94
ENZY's Price/Net Current Asset Value is ranked higher than
85% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. ENZY: 1.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.93  Med: 2.9 Max: 14.91
Current: 1.94
1.93
14.91
Price/Tangible Book 1.04
ENZY's Price/Tangible Book is ranked higher than
91% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ENZY: 1.04 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.03  Med: 1.47 Max: 6.82
Current: 1.04
1.03
6.82
Price/Median PS Value 0.81
ENZY's Price/Median PS Value is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ENZY: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.06 Max: 1.28
Current: 0.81
0.39
1.28
Price/Graham Number 1.61
ENZY's Price/Graham Number is ranked higher than
65% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. ENZY: 1.61 )
Ranked among companies with meaningful Price/Graham Number only.
ENZY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.88  Med: 1.54 Max: 3.35
Current: 1.61
0.88
3.35
Earnings Yield (Greenblatt) (%) 3.00
ENZY's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ENZY: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 4.1 Max: 13.9
Current: 3
1.9
13.9

More Statistics

Revenue (TTM) (Mil) $50.38
EPS (TTM) $ 0.11
Beta1.00
Short Percentage of Float0.26%
52-Week Range $5.20 - 10.32
Shares Outstanding (Mil)22.72

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 56 65
EPS ($) 0.25 0.50
EPS w/o NRI ($) 0.25 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Julian Robertson Cuts Half of Stake in Paulson-Backed Company Jul 01 2016 
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
2016-12-01 Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors Dec 01 2016
2016-12-01 Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ) Dec 01 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Enzymotec downgraded by Wells Fargo Nov 17 2016
Edited Transcript of ENZY earnings conference call or presentation 16-Nov-16 1:30pm GMT Nov 16 2016
Enzymotec Ltd. Announces Departure of its CEO Nov 16 2016
Enzymotec reports 3Q loss Nov 16 2016
Enzymotec reports 3Q loss Nov 16 2016
Enzymotec Ltd. Announces Departure of its CEO Nov 16 2016
Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results Nov 16 2016
Q3 2016 Enzymotec Ltd Earnings Release - Before Market Open Nov 16 2016
2016-11-03 Enzymatica AB: ColdZyme® sales continue to perform well Nov 03 2016
2016-11-02 Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Nov 02 2016
Enzymotec to Report Third Quarter 2016 Financial Results Nov 02 2016
Enzymotec to Report Third Quarter 2016 Financial Results Nov 02 2016
Enzymotec Ltd. Granted New Patents for INFAT® in the U.S., Vayacog® in Japan and... Sep 27 2016
2016-08-30 Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share... Aug 30 2016
Edited Transcript of ENZY earnings conference call or presentation 9-Aug-16 12:30pm GMT Aug 19 2016
Should You Get Rid of Enzymotec (ENZY) Now? Aug 18 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)